Ranolazine, a novel agent for chronic stable angina

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 135-142

  Gaffney, Sarah M ^a  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

Chronic stable angina; Pharmacokinetics; Pharmacologic treatment guidelines; Ranolazine

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FATTY ACID OXIDASE INHIBITOR; GLYCERYL TRINITRATE; NIFEDIPINE; NITRIC ACID DERIVATIVE; PLACEBO; RANOLAZINE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANGINA PECTORIS; ASTHENIA; CHRONIC STABLE ANGINA; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; ENZYME REGULATION; FATIGUE; FATTY ACID OXIDATION; HEADACHE; HUMAN; ISCHEMIC HEART DISEASE; LIVER DISEASE; NAUSEA; OXYGEN CONSUMPTION; PHASE 3 CLINICAL TRIAL; SHORT SURVEY; SYNCOPE; TACHYCARDIA;

ANGINA PECTORIS; CHRONIC DISEASE; CLINICAL TRIALS; ENZYME INHIBITORS; GUIDELINES; HUMANS; PIPERAZINES;

EID: 30544436406     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.135     Document Type: Short Survey

References (28)

1. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1999 guidelines for the management of patients with chronic stable angina). 2002. Available from www.acc.org/clinical/ guidelines/stable/stable. pdf. Accessed August 1, 2005.
2. Gersh BJ, Braunwald E, Rutherford JD. Chronic coronary artery disease. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 5th ed, vol 2, chapter 38 (international version). Philadelphia, PA: W.B. Saunders Co, 1997.
3. Talbert RL. Ischemic heart disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed, chapter 14 (international edition). New York, NY: McGraw-Hill, 2002.
4. CV Therapeutics, Inc. Products in development: angina. Available from www.cvt.com. Accessed February 19, 2005.
5. Klasco RK, ed. Ranolazine. In: Drugdex system. Greenwood Village, CO: Thomson Micromedex, vol 123. Expires March 2005.
6. Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997;95:313-15.
7. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev 2002;7:161-73.
8. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135-42.
9. McCormack JG, Stanley WC, Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998;30:639-45.
10. Chaitman BR. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor. Curr Probl Cardiol 2002;27:527-55.
11. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-41.
12. Fleming R, Nissen SE, Borer JS, Armstrong PW. Report from the 100th cardiovascular and renal drugs advisory committee meeting, U.S. Food and Drug Administration: December 8-9, 2003, Gaithersburg, MD [online exclusive article]. Circulation 2004;109:e9004-5. Available from http://circ.ahajournals.org/cgi/ content/full/109/2/e9004. Accessed July 6, 2005.
13. Yang EH, Barsness GW, Gersh BJ, Chandrasekaran K, Lerman A. Current and future treatment strategies for refractory angina. Mayo Clin Proc 2004;79:1284-92.
14. Hooper JS, Busti AJ. Ranolazine as add-on therapy for patients with severe chronic angina [letter]. JAMA 2004;291:1959.
15. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82.
16. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents: ranolazine study group. Am J Cardiol 1999;84:46-50.
17. Wolff AA, for the MARISA Investigators. Monotherapy assessment of ranolazine in stable angina [abstr]. J Am Coll Cardiol 2000;35(suppl 1):408A.
18. Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris: ranolazine study group. Circulation 1994;90:726-34.
19. Chaitman BR, Pepine CJ, Parker JO, et al, for the Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina, a randomized controlled trial. JAMA 2004;291:309-16.
20. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-16.
21. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-8.
22. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005;45:802-9.
23. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005;45:422-33.
24. Hughes S. Fears over QT prolongation shadow new drugs: ranolazine now under fire. HeartWire > News, June 6, 2002.
25. Wood S. No formal vote on ranolazine by FDA's cardiovascular/renal drugs committee: more data needed. HeartWire > News, December 10, 2003.
26. Wood S. Ranolazine for angina in the modern PCI/CABG era: which patients, which therapies? HeartWire > News, January 20, 2004.
27. Berger P. Ranolazine and other antianginal therapies in the era of the drug-eluting stent [editorial]. JAMA 2004;291:365-7.
28. Pechlaner C, Wiedermann C. Ranolazine as add-on therapy for patients with severe chronic angina [letter]. JAMA 2004;291:1959.